Esophageal Cancer Pipeline H1 2016 Market Report on 54 Companies

PUNE, India, May 5, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Esophageal Cancer - Pipeline Review, H1 2016" market research report that offers comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Esophageal Cancer with 83 market data tables and 16 figures, spread across 448 pages is available at http://www.rnrmarketresearch.com/esophageal-cancer-pipeline-review-h1-2016-market-report.html .

The report also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Esophageal Cancer Pipeline Review, H1 2016 report include Adaptimmune Therapeutics Plc, Advantagene, Inc., Advaxis, Inc., Advenchen Laboratories, LLC, Almac Discovery Limited, Amgen Inc., ArQule, Inc., Array BioPharma Inc., Aslan Pharmaceuticals Pte. Ltd., ATLAB Pharma SAS, Bayer AG, Betta Pharmaceuticals Co. Ltd., Boehringer Ingelheim GmbH, Celgene Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Cerulean Pharma, Inc., Cyclacel Pharmaceuticals, Inc., Genmab A/S, Glycotope GmbH, Hutchison MediPharma Limited, Ignyta, Inc., ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., Komipharm International Co., Ltd., MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Merck & Co., Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Proteo, Inc., Puma Biotechnology, Inc., Shenzen SiBiono GeneTech Co., Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Spectrum Pharmaceuticals, Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Taiho Pharmaceutical Co., Ltd., Taiwan Liposome Company, Ltd., Takara Bio Inc., tella Inc, TG Therapeutics, Inc., Transgene Biotek Limited, VioQuest Pharmaceuticals, Inc. and Virocan Therapeutics Private Limited.